1113014-53-1

Basic information

• Product Name: 2-[4'-(2-Fluoroethyl)aMinophenyl]-6-hydroxybenzothiazole
• Synonyms: 2-[4'-(2-Fluoroethyl)aMinophenyl]-6-hydroxybenzothiazole;FBTA
• CAS NO: 1113014-53-1
• Molecular Formula: C₁₅H₁₃FN₂OS
• Molecular Weight: 288.3399232
• Mol File: 1113014-53-1.mol
• Article Data: 1

Chemical Properties

• Melting Point: 194-196 °C
• Boiling Point: 501.3±60.0 °C(Predicted)
• Appearance: /
• Density: 1.364±0.06 g/cm3(Predicted)
• PKA: 8.61±0.40(Predicted)
• CAS DataBase Reference: 2-[4'-(2-Fluoroethyl)aMinophenyl]-6-hydroxybenzothiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[4'-(2-Fluoroethyl)aMinophenyl]-6-hydroxybenzothiazole(1113014-53-1)
• EPA Substance Registry System: 2-[4'-(2-Fluoroethyl)aMinophenyl]-6-hydroxybenzothiazole(1113014-53-1)

Safety Data

• Hazardous Substances Data: 1113014-53-1(Hazardous Substances Data)

Usage

General Description

2-[4'-(2-Fluoroethyl)aminophenyl]-6-hydroxybenzothiazole is a chemical compound with a molecular formula C16H14FNO2S. 2-[4'-(2-Fluoroethyl)aminophenyl]-6-hydroxybenzothiazole is used as a fluorescent marker for amyloid plaques in the brain, which are associated with Alzheimer's disease. It is also a potential tool for studying the deposition and aggregation of amyloid proteins. Additionally, this compound is being investigated for its potential use in early diagnosis and monitoring of Alzheimer's disease progression. Its unique structure and properties make it an important tool in the field of neuroscience and neurodegenerative diseases.

Relevant articles and documents

Synthesis of a [18F]fluorobenzothiazole as potential amyloid imaging agent

This study describes the synthesis of a fluoroethylated derivative of [N-methyl-11C]2-(4′-methylaminophenyl)-6-hydroxybenzothiazole ([11C]6-OH-BTA-1; Pittsburgh Compound B (PIB)), an already established amyloid imaging agent. The [11C]methylamino group of [11C]6-OH-BTA-1 was formally replaced by a fluoroethyl group in a cold synthesis via N-alkylation of N-Boc-2-(4′-aminophenyl)-6- (methoxyethoxymethoxy)benzothiazole with fluoroethyl tosylate. Subsequent deprotection gave the target compound 2-[4′-(2-fluoroethyl)aminophenyl]-6- hydroxybenzothiazole (FBTA). In a radioligand competition assay on aggregated synthetic amyloid fibrils using N-[3H-methyl]6-OH-BTA-1, 100 nM FBTA inhibited binding with 93 ± 1 and 83 ± 1% efficiency for Aβ1-40 and Aβ1-42, respectively. For the radiosynthesis a precursor carrying a tosylethyl moiety was prepared allowing the introduction of [18F]fluoride via nucleophilic substitution with [18F]tetra-n-butyl-ammonium fluoride (TBAF). Subsequent removal of all protecting groups was performed in a one-pot procedure followed by semi-preparative HPLC, delivering the target compound [18F]FBTA in good radiochemical yield of 21% on average and radiochemical purity of ≥98% at EOS. In vitro autoradiography on human postmortem AO brain tissue slices showed intense cortical binding of [18F]FBTA (1 nM), which was displaced in presence of 6-OH-BTA-1 (1 μM). Brain up-take was evaluated in wild-type (wt) mice with microPET imaging. Based on these results, [ 18F]FBTA appears to be a suitable candidate tracer for amyloid imaging in humans. Copyright